California Governor Brown Signs Bill Ensuring Patient Access to Interchangeable Biologic Medicines

Communication Important for Patients and Physicians

2015 BIO Patient and Health Advocacy Summit Draws Record 325 Attendees

Washington, DC (October 7, 2015) – The fourth annual BIO Patient and Health...

Stanford and BIO Announce New SPARK Showcase Event at 14th Annual BIO Investor Forum

The Stanford University School of Medicine and BIO announce a new program – the SPARK Showcase Event – to feature the latest academic research for venture capital firms and business development executives seeking opportunities to expand their pipelines. The symposium will feature a keynote speech by Dr. Daria Mochly-Rosen, SPARK Director and George D. Smith Professor in Translational Medicine, Stanford University School of Medicine.

BIO Statement on Data Exclusivity Provisions Within the Trans-Pacific Partnership


BIO Announces Complete Program Lineup for 14th Annual BIO Investor Forum

BIO announces the final program and speakers for the 14th Annual BIO Investor Forum, an international investor forum which explores investment trends and opportunities in life sciences.  The event focuses on early and mid-stage private as well as emerging public companies that are poised for growth in 2016. The event will take place October 20-21, 2015, at the Parc 55 in San Francisco, California.

BIO Submits Comments Re: CMS HCPCS Public Meeting

RE: Centers for Medicare and Medicaid Services Healthcare Common Procedure Coding System Public Meeting, May 7, 2015   Dear Ms. Carver:   The Biotechnology Industry Organization (BIO) is pleased to provide comments in response to the May 7 Centers for Medicare and Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) Public Meeting Agenda for Drugs, Biologicals and Radiopharmaceuticals (“Public Meeting Agenda”).

BIO Statement Concerning the Recent Ruling Issued by the PTO’s Patent Trial and Appeal Board

"It is disappointing that the PTO’s Patent Trial and Appeal Board (PTAB) failed to properly assess the important issues raised by this motion. This cursory and erroneous ruling reinforces the immediate need for Congress and the PTO leadership to take clear and decisive action to prevent any further misuse and abuse of the Inter Partes Review process by hedge funds, extortionists and other questionable entities seeking to undermine it for their own financial benefit." 

Clinton Campaign Proposal Would Hamper Patient Access To Innovative New Cures and Therapies

“The proposal released today by the Clinton campaign would do irreparable harm to the nation’s health innovation system, significantly hindering the ability of emerging biotechnology companies to develop the new cures and therapies that patients need to live longer, more productive lives...

BIO Issues 2016 BIO International Convention Call for Sessions & Speakers

BIO calls on biopharmaceutical, business development, life sciences and policy experts to submit thought-provoking and timely proposals for sessions and speakers at the 2016 BIO International Convention. BIO 2016 will be held June 6-9, 2016 in San Francisco, California.

BIO Statement on Nomination of Dr. Robert Califf as FDA Commissioner

BIO President and CEO Jim Greenwood released the following statement today commending President Barack Obama for his nomination of Dr. Robert Califf as Commissioner of the Food and Drug Administration (FDA):